Navigation Links
Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results
Date:8/17/2008

1, 2008. Separately, the Centers for Medicare & Medicaid Services proposed to reimburse Zevalin based on the Average Sales Price methodology, which is currently used for drugs and biologicals, in 2009.

-- Completed enrollment for phase II clinical trial of brostallicin as first-line therapy in patients with newly diagnosed advanced or metastatic soft tissue sarcoma.

-- Announced that Craig Philips, most recently Vice President and General Manager of Bayer Healthcare Oncology, assumed day to day role as President of CTI with direct responsibilities for development and commercial operations.

-- Repaid balance of approximately $10.7 million for 2008 Convertible Notes leaving Company with no debt maturing before Q3 2010 and established equity line of credit for the sale of up to $12 million of common stock over time.

Total operating expenses increased to $28.7 million for the quarter ended June 30, 2008 compared to $24.3 million for the same period in 2007 mainly as a result of increased expenses related to support expansion of Zevalin sales and marketing efforts and legal expenses. Net loss attributable to common shareholders for the quarter ended June 30, 2008, totaled $59.3 million ($0.52 per share), which included $25.6 million in make-whole interest expense due to the conversion of the 9% and 13.5% convertibles notes into common stock that resulted in a decrease of approximately $39.6 million in debt, compared to $27.9 million ($0.65 per share) for the comparable period in 2007. The decrease in net loss per share is due to an increase in the number of shares outstanding.

The Company had approximately $12.4 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of June 30, 2008. This does not include $26.9 million in restricted cash held in escrow for future make-whole and interest payments on our 9%, 13.5% and 15% convertible notes as well as net cash proceeds of approximately $4.5 million
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 ... maker of MD-Cu 29 antimicrobial copper, announces Gilmour ... points to the first EPA-registered antimicrobial solid touch surface ... copper is a reasonably priced surface that kills greater ... 2 hours of exposure. 1 ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , Jan. 12 Novavax, Inc. (Nasdaq: ... pre-clinical safety and efficacy study of its RSV vaccine candidate ... support an Investigational New Drug (IND) application to advance this ... into clinical development.  This vaccine candidate is composed of recombinant ...
... ... a standalone Windows® desktop application for viewing eCTD submissions created for any region. ... Marlborough, MA (PRWEB) January 12, ... for the life sciences industry, today announced the release of Datafarm VUE, a new addition ...
... ... VA, will discuss practical approaches to President Obama’s challenges to "find the needle in ... ... connect the dots” on the Christmas bomber in his recent address to the Nation. ...
Cached Biology Technology:NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 2NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 3NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 4NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 5Datafarm Releases New Desktop-based Application for Multi-region Viewing of eCTD Submissions: Datafarm VUE 2NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2
(Date:9/16/2014)... school biology taught us that we inherit certain traits ... you could change how these genes play out by ... diet? That,s exactly what a team of researchers ... proposed through their research of epigenetics research. , ... chemically modifying DNA and histone proteins, which prevent permanent ...
(Date:9/16/2014)... own bacterial identity. That,s the conclusion of University of ... the genetic fingerprints of bacteria on 57 species of ... demonstrates for the first time that host plants from ... very different microbial communities on their leaves," said lead ... the UO,s Institute of Ecology and Evolution who is ...
(Date:9/16/2014)... 10-km diameter chunk of rock hit the Yukatan peninsula near ... force of 100 teratons of TNT. It left a crater ... global earthquakes and volcanism are widely accepted to have wiped ... the mammals. But what happened to the plants on which ... from the University of Arizona reveals that the meteorite impact ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
COMING SOON: Anti-Mouse C5a Receptor (CD88), Clone 10/92 Monoclonal Antibody...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: